

Proposal for resolution on issue authorisation

The board of directors of Biosergen AB, Reg. No. 559304-1295, proposes that the annual general meeting on 31 May 2023 resolves to authorise the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to issue shares, convertibles and/or warrants. The reason for why a deviation from the shareholders' preferential rights should be possible is to enable the company to source working capital, to be able to execute acquisitions of companies or operating assets as well as to enable new issues to industrial partners within the framework of partnerships and alliances.

In case the authorisation is used for a new issue with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting.

The company's CEO shall be authorized to make minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (*Sw.* Bolagsverket).

Malmö in April 2023
Biosergen AB (publ)
The Board of Directors